ARJO-B Arjo AB (publ)
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, hygiene, prevention of pressure injuries and blood clots, and leg ulcer treatment and prevention, as well as for obstetric and cardiac diagnostics. The company also provides dementia care, bariatric room solutions, prone positioning, early mobility, architects and planners, and rehabilitation services, as well as equipment repair and maintenance, and equipment rental and financing solutions. It serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden.…
Industry Peers
Medical DistributionKey Statistics
About Arjo (STO: ARJO-B)
›
Arjo (STO: ARJO-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 7,000 employees.
The shares were at 36.24 SEK on 19 November 2026, up 23.2% over 52 weeks. Its 52-week range is 23.64 SEK to 37.26 SEK: the price is 2.7% below the high and 53.3% above the low.
At a market capitalisation of 9.87B SEK, it trades at 27.2 times trailing earnings and 13.5 times forward earnings. The median trailing P/E of its 17 largest Medical Distribution peers is 20.3, a premium of 34% for ARJO-B. It pays a dividend yielding 2.61% (it pays out 71% of its earnings), against a median of 1.38% among the dividend payers in that peer group.
Arjo reports return on equity of 4.5%, an operating margin of 8.5% and revenue up 7.7% year over year.
Its debt exceeds its cash by 4.53B SEK, a debt-to-equity ratio of 0.72. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 34.80 SEK is 4.0% below the current price. The next earnings report is expected on 28 January 2027.